Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 304

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Radiation Therapy and Tamoxifen: Concurrent or Sequential? That Is the Question

Whelan, Timothy, Levine, Mark·2005·Journal of Clinical Oncology

Abstract

Randomized controlled trials have had an important impact on the treatment of women with early breast cancer. Many women routinely receive breast-conserving surgery plus radiation therapy, adjuvant chemotherapy, or hormonal therapy based on the results of randomized trials. However, despite the extensive use of combinations of chemotherapy, hormonal therapy, and radiation therapy, the optimal sequencing of these different adjuvant treatments for patients with early breast cancer remains unclear. Unfortunately, there have been few randomized trials addressing this important issue. In a randomized trial by Recht et al, 1 the optimal sequencing of radiation and chemotherapy in patients treated with breast-conserving surgery was evaluated. Of 244 patients, 122 were allocated to receive radiation therapy before anthracycline-based chemotherapy and 122 were allocated to receive radiation therapy after the same chemotherapy. The median length of follow-up was 58 months. Although the study was relatively small by today’s standards, there was a trend for an increased risk of distant recurrence for patients treated with radiation therapy first (36% v 25%; hazard ratio [HR], 1.62; 95% CI, 1.01 to 2.62;P .05). As a result, breast irradiation is now usually given after anthracycline-based chemotherapy. In early 1990s, investigators from the North American Breast Intergroup conducted a randomized trial in postmenopausal women with node-positive, hormone receptor–positive breast cancer, which compared tamoxifen, administered concurrently with cyclophosphamide, doxorubicin, and fluorouracil (n 550) with tamoxifen given after the completion of the same chemotherapy (n 566). 2 This was an important clinical question because there was some concern that the cytostatic effect of concurrent tamoxifen might interfere with the cytotoxic effects of chemotherapy on cancer cells. Preclinical data had demonstrated that human breast tumor cells in culture pretreated with tamoxifen were protected from the cytotoxicity of chemotherapy. 3 This concern was not shared by all investigators; several cooperative groups recommended the concurrent use of chemotherapy and tamoxifen in trials evaluating these agents. Furthermore, it had already been observed that combined chemotherapy and tamoxifen increased the risk of thromboembolic complications in patients. 4 With a median follow-up of 8.5 years, the results of the Intergroup study were presented at the 2000 American Society of Clinical Oncology Annual Meeting. The 8-year disease-free survival estimates were 67% for patients treated with sequential chemotherapy and tamoxifen compared with 62% for patients treated with concurrent chemotherapy and tamoxifen (P .05). 2 This study led to important

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2005.08.955

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 15 references

Cited by

See all 304

Metadata

Authors
Whelan, T., & Levine, M.
Venue
Journal of Clinical Oncology
Published
2005-01-01
Volume
23
Issue
1
Pages
1-4
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2101020979
Cited by
304
References
15
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Radiation Therapy and Tamoxifen: Concurrent or Sequential? That Is the Question. https://app.cochat.ai/papers/10.1200/jco.2005.08.955
The paper
Whelan, T., & Levine, M. (2005). Radiation Therapy and Tamoxifen: Concurrent or Sequential? That Is the Question. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2005.08.955

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.